Literature DB >> 10558898

In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis.

M Yoshida1, J Sakuma-Mochizuki, K Abe, T Arai, M Mori, S Goya, H Matsuoka, S Hayashi, Y Kaneda, T Kishimoto.   

Abstract

A number of investigators have reported augmented expression of PDGF in lungs with idiopathic pulmonary fibrosis (IPF) or with other types of pulmonary fibrosis. To accomplish such a regulation of PDGF activity, we constructed an expression plasmid of the extracellular domain of PDGF receptor beta chain (XR), which lacks intracellular tyrosine kinase domain and transmembrane portions, and estimated the therapeutic effects of XR gene transfer through the trachea on bleomycin-induced lung fibrosis of C57BL/6 mice using the hemagglutinating virus of Japan(HVJ)-liposome method. The XR gene transfer ameliorated the increases in the wet weight and hydroxyproline content and the histopathologic changes of the lung induced by bleomycin. These findings suggest that PDGF plays a crucial role in the pathogenesis of pulmonary fibrosis, and that XR gene transfer using the HVJ-liposome method may limit the progression of pulmonary fibrosis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10558898     DOI: 10.1006/bbrc.1999.1647

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

2.  [Localisation of TGF-beta and PDGF and their relevance for the pathogenesis of arthrofibrosis].

Authors:  J Zeichen; L Haeder; M Jagodzinski; P Lobenhoffer; U Bosch; J Brand
Journal:  Unfallchirurg       Date:  2008-02       Impact factor: 1.000

3.  Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats.

Authors:  W A Dik; R J McAnulty; M A Versnel; B A E Naber; L J I Zimmermann; G J Laurent; S E Mutsaers
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 4.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 5.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

6.  Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.

Authors:  Chin Kook Rhee; Sang Haak Lee; Hyung Kyu Yoon; Seok Chan Kim; Sook Young Lee; Soon Suk Kwon; Young Kyoon Kim; Kwan Hyoung Kim; Tae Jung Kim; Jin Woo Kim
Journal:  Respiration       Date:  2011-06-09       Impact factor: 3.580

7.  Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.

Authors:  Hideto Kameda; Miyuki Suzuki; Tsutomu Takeuchi
Journal:  Drug Target Insights       Date:  2007-10-30

Review 8.  Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Authors:  Minoru Inomata; Yasuhiko Nishioka; Arata Azuma
Journal:  Core Evid       Date:  2015-08-27

Review 9.  The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.

Authors:  Lucy A Murtha; Michael J Schuliga; Nishani S Mabotuwana; Sean A Hardy; David W Waters; Janette K Burgess; Darryl A Knight; Andrew J Boyle
Journal:  Front Physiol       Date:  2017-10-12       Impact factor: 4.566

10.  Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Masami Kishi; Yoshinori Aono; Seidai Sato; Kazuya Koyama; Momoyo Azuma; Shuichi Abe; Hiroshi Kawano; Jun Kishi; Yuko Toyoda; Hiroyasu Okazaki; Hirohisa Ogawa; Hisanori Uehara; Yasuhiko Nishioka
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.